Gastrointestinal stromal tumor differential diagnosis: Difference between revisions
Jump to navigation
Jump to search
Akshun Kalia (talk | contribs) No edit summary |
|||
| (6 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
[[Image:Home_logo1.png|right|250px|link=https://www.wikidoc.org/index.php/Gastrointestinal_stromal_tumor]] | |||
{{CMG}};{{AE}}{{Akshun}}{{PSD}} | {{CMG}};{{AE}}{{Akshun}}{{PSD}} | ||
==Overview== | ==Overview== | ||
Around 75 % of the [[Patient|patients]] with gastrointestinal stromal tumors (GIST) are [[asymptomatic]] and the rest have non-specific [[Symptom|symptoms]] such as vague [[abdominal]] [[pain]] and discomfort. Thus, GIST must be differentiated from other [[Tumor|tumors]] on the basis of [[Cell (biology)|cell]] markers. GIST must be differentiated from other [[mesenchymal]] [[Tumor|tumors]] such as gastrointestinal [[leiomyoma]], [[gastrointestinal]] [[leiomyosarcoma]], [[gastrointestinal]] [[carcinoma]], [[gastrointestinal]] [[schwannoma]] and [[melanoma]]. | |||
==Differential Diagnosis== | ==Differential Diagnosis== | ||
Around 75 % of the patients with gastrointestinal stromal tumors (GIST) are asymptomatic and the rest have non-specific symptoms such as vague abdominal pain and discomfort. Thus, GIST must be differentiated from other tumors on the basis of cell markers. GIST must be differentiated from other mesenchymal tumors such as gastrointestinal [[leiomyoma]], gastrointestinal [[leiomyosarcoma]], gastrointestinal [[carcinoma]], gastrointestinal [[schwannoma]] and [[melanoma]].<ref name="pmid15215166">{{cite journal |vauthors=West RB, Corless CL, Chen X, Rubin BP, Subramanian S, Montgomery K, Zhu S, Ball CA, Nielsen TO, Patel R, Goldblum JR, Brown PO, Heinrich MC, van de Rijn M |title=The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status |journal=Am. J. Pathol. |volume=165 |issue=1 |pages=107–13 |year=2004 |pmid=15215166 |pmc=1618538 |doi=10.1016/S0002-9440(10)63279-8 |url=}}</ref> | Around 75 % of the [[Patient|patients]] with gastrointestinal stromal tumors (GIST) are [[asymptomatic]] and the rest have non-specific [[Symptom|symptoms]] such as vague [[Abdomen|abdominal]] [[pain]] and [[discomfort]]. Thus, GIST must be differentiated from other [[Tumor|tumors]] on the basis of [[Cell (biology)|cell]] markers. GIST must be differentiated from other [[mesenchymal]] [[Tumor|tumors]] such as [[gastrointestinal]] [[leiomyoma]], [[gastrointestinal]] [[leiomyosarcoma]], [[gastrointestinal]] [[carcinoma]], [[gastrointestinal]] [[schwannoma]] and [[melanoma]].<ref name="pmid15215166">{{cite journal |vauthors=West RB, Corless CL, Chen X, Rubin BP, Subramanian S, Montgomery K, Zhu S, Ball CA, Nielsen TO, Patel R, Goldblum JR, Brown PO, Heinrich MC, van de Rijn M |title=The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status |journal=Am. J. Pathol. |volume=165 |issue=1 |pages=107–13 |year=2004 |pmid=15215166 |pmc=1618538 |doi=10.1016/S0002-9440(10)63279-8 |url=}}</ref><ref>{{Cite web | title =Gastrointestinal stromal tumour | url = http://radiopaedia.org/articles/gastrointestinal-stromal-tumour-1}}</ref><ref name="pmid27178821">{{cite journal |vauthors=Baskin Y, Kocal GC, Kucukzeybek BB, Akbarpour M, Kayacik N, Sagol O, Ellidokuz H, Oztop I |title=PDGFRA and KIT Mutation Status and Its Association With Clinicopathological Properties, Including DOG1 |journal=Oncol. Res. |volume=24 |issue=1 |pages=41–53 |year=2016 |pmid=27178821 |doi=10.3727/096504016X14576297492418 |url=}}</ref><ref name="pmid1731347">{{cite journal |vauthors=Gerhart DZ, Broderius MA, Borson ND, Drewes LR |title=Neurons and microvessels express the brain glucose transporter protein GLUT3 |journal=Proc. Natl. Acad. Sci. U.S.A. |volume=89 |issue=2 |pages=733–7 |year=1992 |pmid=1731347 |pmc=48313 |doi= |url=}}</ref> | ||
{| class="wikitable" | {| class="wikitable" | ||
!Marker | ! style="background: #4479BA; color: #FFFFFF; " |Marker | ||
!GIST | ! style="background: #4479BA; color: #FFFFFF; " |GIST | ||
!GI leiomyoma | ! style="background: #4479BA; color: #FFFFFF; " |GI leiomyoma | ||
!GI Leiomyosarcoma | ! style="background: #4479BA; color: #FFFFFF; " |GI Leiomyosarcoma | ||
!Schwannoma | ! style="background: #4479BA; color: #FFFFFF; " |Schwannoma | ||
!GI | ! style="background: #4479BA; color: #FFFFFF; " |GI Carcinoma | ||
!Melanoma | ! style="background: #4479BA; color: #FFFFFF; " |Melanoma | ||
|- | |- | ||
|CD117 | |CD117 | ||
| Line 46: | Line 44: | ||
|Other | |Other | ||
Markers | Markers | ||
|Desmin positive | |[[Desmin]] positive | ||
in 1-2% | in 1-2% | ||
|Desmin positive in | |[[Desmin]] positive in | ||
100% cases | 100% cases | ||
|Desmin positive but | |[[Desmin]] positive but | ||
variable proportion | variable proportion | ||
|GFAP positive | |GFAP positive | ||
|Keratin positive | |[[Keratin]] positive | ||
|S100 positive | |S100 positive | ||
|} | |} | ||
Latest revision as of 15:33, 5 March 2019
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Akshun Kalia M.B.B.S.[2]Parminder Dhingra, M.D. [3]
Overview
Around 75 % of the patients with gastrointestinal stromal tumors (GIST) are asymptomatic and the rest have non-specific symptoms such as vague abdominal pain and discomfort. Thus, GIST must be differentiated from other tumors on the basis of cell markers. GIST must be differentiated from other mesenchymal tumors such as gastrointestinal leiomyoma, gastrointestinal leiomyosarcoma, gastrointestinal carcinoma, gastrointestinal schwannoma and melanoma.
Differential Diagnosis
Around 75 % of the patients with gastrointestinal stromal tumors (GIST) are asymptomatic and the rest have non-specific symptoms such as vague abdominal pain and discomfort. Thus, GIST must be differentiated from other tumors on the basis of cell markers. GIST must be differentiated from other mesenchymal tumors such as gastrointestinal leiomyoma, gastrointestinal leiomyosarcoma, gastrointestinal carcinoma, gastrointestinal schwannoma and melanoma.[1][2][3][4]
| Marker | GIST | GI leiomyoma | GI Leiomyosarcoma | Schwannoma | GI Carcinoma | Melanoma |
|---|---|---|---|---|---|---|
| CD117 | Positive (95%) | Negative | Negative | Negative | Positive (50%) | Positive |
| CD34 | Positive (70%) | Negative | Negative | Positive (33%) | Negative | Negative |
| DOG 1 | Positive (95%) | Negative | Negative | Negative | Negative | Rare |
| Other
Markers |
Desmin positive
in 1-2% |
Desmin positive in
100% cases |
Desmin positive but
variable proportion |
GFAP positive | Keratin positive | S100 positive |
References
- ↑ West RB, Corless CL, Chen X, Rubin BP, Subramanian S, Montgomery K, Zhu S, Ball CA, Nielsen TO, Patel R, Goldblum JR, Brown PO, Heinrich MC, van de Rijn M (2004). "The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status". Am. J. Pathol. 165 (1): 107–13. doi:10.1016/S0002-9440(10)63279-8. PMC 1618538. PMID 15215166.
- ↑ "Gastrointestinal stromal tumour".
- ↑ Baskin Y, Kocal GC, Kucukzeybek BB, Akbarpour M, Kayacik N, Sagol O, Ellidokuz H, Oztop I (2016). "PDGFRA and KIT Mutation Status and Its Association With Clinicopathological Properties, Including DOG1". Oncol. Res. 24 (1): 41–53. doi:10.3727/096504016X14576297492418. PMID 27178821.
- ↑ Gerhart DZ, Broderius MA, Borson ND, Drewes LR (1992). "Neurons and microvessels express the brain glucose transporter protein GLUT3". Proc. Natl. Acad. Sci. U.S.A. 89 (2): 733–7. PMC 48313. PMID 1731347.